# A Prospective Post-Marketing Observational Safety Study of Verzenios® (Abemaciclib) Among Breast Cancer Patients in China Verzenios® (Abemaciclib) Among Breast

> **NCT05267327** · — · NOT_YET_RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 1500 (estimated)

## Conditions studied

- The Incidence of AEs and SAEs Receiving Verzenios® Over a Period of Approximately 24 Weeks

## Interventions

- **OTHER:** Verzenios

## Key facts

- **NCT ID:** NCT05267327
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2022-03
- **Primary completion:** 2024-06
- **Final completion:** 2026-05
- **Target enrollment:** 1500 (ESTIMATED)
- **Last updated:** 2022-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05267327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05267327, "A Prospective Post-Marketing Observational Safety Study of Verzenios® (Abemaciclib) Among Breast Cancer Patients in China Verzenios® (Abemaciclib) Among Breast". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05267327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*